支气管痉挛治疗市场（2026—2031）
Mordor 预计，支气管痉挛治疗市场规模将由2026年的45.2亿美元增至2031年的61.6亿美元，期间复合年增长率为6.40%。2025年支气管扩张剂占52.56%，吸入给药占47.76%，医院占62.88%。北美为最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
Mordor 预计，支气管痉挛治疗市场规模将由2026年的45.2亿美元增至2031年的61.6亿美元，期间复合年增长率为6.40%。2025年支气管扩张剂占52.56%，吸入给药占47.76%，医院占62.88%。北美为最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.4% | 机构预测 |
| 市场规模 | 2026 | USD 4.52 billion | 机构预测 |
| 市场规模 | 2031 | USD 6.16 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end_user | hospitals | 2025 | 62.880% |
| geography | North America | 2025 | 42.440% |
| patient_age | adult patients | 2025 | 58.660% |
| route_of_administration | inhalational delivery | 2025 | 47.760% |
| treatment | bronchodilators | 2025 | 52.560% |
关键结论
- end_user 维度中，hospitals 在 2025 年的公开份额为 62.88%。
- geography 维度中，North America 在 2025 年的公开份额为 42.44%。
- patient_age 维度中，adult patients 在 2025 年的公开份额为 58.66%。
- route_of_administration 维度中，inhalational delivery 在 2025 年的公开份额为 47.76%。
- treatment 维度中，bronchodilators 在 2025 年的公开份额为 52.56%。
主要参与者
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- GSK plc
- Merck & Co., Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising asthma and COPD burden globally | +2.100% | Global | Long term (≥ 4 years) |
| Exposure to air pollution and occupational irritants | +1.300% | APAC, MEA, South America, Eastern Europe | Long term (≥ 4 years) |
| Combination and long-acting bronchodilator therapy | +1.400% | North America, Europe, APAC | Medium term (2-4 years) |
| Affordable generic inhaler supply | +0.900% | South Asia, South America, MEA | Medium term (2-4 years) |
| Diagnosis of severe and eosinophilic asthma | +0.800% | North America, Europe, Japan | Medium term (2-4 years) |
| Connected inhalers and home-based respiratory care | +0.800% | North America, Europe, Australia | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Inhaler-use errors and treatment-adherence gaps | -0.900% | Global, especially LMICs | Long term (≥ 4 years) |
| Safety concerns with corticosteroids and bronchodilators | -0.700% | Global | Medium term (2-4 years) |
| Pricing pressure from generic and tender-based procurement | -0.800% | Europe, South Asia, South America | Medium term (2-4 years) |
| Unequal availability of essential inhaled medicines | -0.700% | MEA, South-East Asia, South America | Long term (≥ 4 years) |
报告关注的关键问题
What is the forecast value of bronchial spasm treatment demand by 2031?
The bronchial spasm market is forecast to reach USD 6.16 billion by 2031, from USD 4.52 billion in 2026, at a 6.40% CAGR.
Which treatment category holds the largest share in bronchial spasm care?
Bronchodilators held 52.56% of revenue in 2025 because they are widely used for acute relief and maintenance treatment.
Which bronchial spasm treatment segment is growing the fastest?
Corticosteroids are projected to record the fastest treatment growth at a 9.15% CAGR through 2031, supported by severe asthma care and targeted therapies.
Which route of administration leads bronchial spasm treatment?
Inhalational delivery led with 47.76% share in 2025 because inhalers provide direct and rapid drug delivery to the lungs.
Which region will grow the fastest in bronchial spasm care?
Asia-Pacific is forecast to expand at a 10.88% CAGR through 2031, supported by large asthma populations and increasing treatment access.
Why are connected inhalers important for respiratory care providers?
Connected inhalers can identify poor medicine use, support adherence, and help providers manage patients outside hospitals.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence